Ms. Zaderej has served as Axogen’s President, Chief Executive Officer, and a member of our Board of Directors since September 2011 and the Chairman of our Board of Directors since May 2018. Since May 2010, she has served as the Chief Executive Officer of Axogen’s wholly owned subsidiary, Axogen Corporation, and a member of the Board of Directors of Axogen Corporation. Ms. Zaderej joined Axogen Corporation in May 2006 and served as Vice President of Marketing and Sales from May 2006 to October 2007 and as Chief Operating Officer from October 2007 to May 2010. From October 2004 to May 2006, Ms. Zaderej worked for Zaderej Medical Consulting, a consulting firm she founded to assist medical device companies build and execute successful commercialization plans. From 1987 to 2004, Ms. Zaderej worked at Ethicon, Inc., a Johnson & Johnson company, where she held senior positions in marketing, business development, research & development, and manufacturing. Ms. Zaderej is a member of the University of Tampa Board of Trustees and the MedExec Women Board of Advisors. Ms. Zaderej has an MBA from the Kellogg Graduate School of Business and a B.S. degree in Chemical Engineering from Purdue University.

104. Embracing nerve repair, Karen Zaderej, CEO, Chairman, and President, Axogen

Synopsis: 

John LaMattina is the former President of Global R&D at Pfizer and is currently a Senior Partner at PureTech Health. A self-proclaimed defender of the pharmaceutical industry, Dr. LaMattina worked at Pfizer for 30 years before joining the biotech industry as a board member for a variety of different biotech companies. His recently published book, “Pharma and Profits”, talks about the misconceptions around COVID-19 vaccines and other areas including the cost of drugs, and the impact that the passing of the IRA Act will have on R&D going forward. In this episode he also discusses how biotech leaders should be thinking about the new IRA Act legislation and what changes they should anticipate.

Biography: 
Dr. John L. LaMattina is the former Senior Vice President, Pfizer Inc and President, Pfizer Global Research and Development. In this role, Dr. LaMattina oversaw the drug discovery and development efforts of over 13,000 colleagues in the United States, Europe and Asia. He retired from this position in December, 2007. Dr. LaMattina spent 30 years at Pfizer Inc having joined as a medicinal chemist in 1977. Over the years, he held positions of increasing responsibility for Pfizer Central Research, including Vice President of US Discovery Operations in 1993, Senior Vice President of Worldwide Discovery Operations in 1998 and Senior Vice President of Worldwide Development in 1999.

Dr. LaMattina graduated cum laude from Boston College in 1971 with a B.S. in Chemistry.  He attended the University of New Hampshire receiving a Ph.D. in Organic Chemistry in 1975.  He then moved on to Princeton University as a National Institutes of Health Postdoctoral Fellow in the laboratory of Professor E. C. Taylor.

During his tenure as head of global R&D, Pfizer produced new treatments for cancer, smoking cessation, rheumatoid arthritis and AIDS. Dr. LaMattina is the author of numerous scientific publications and holds a number of U.S. patents.  In addition, he is the author of Drug Truths:  Dispelling the Myths About Pharma R&D and Devalued and Distrusted – Can the Pharmaceutical Industry Restore Its Broken Image?  He is also a Forbes contributor.

Dr. LaMattina has received a number of awards including the 1998 Boston College Alumni Award of Excellence in Science, the 2007 Equal Opportunity Award from Legal Momentum, an Honorary Doctor of Science degree from the University of New Hampshire and the 2010 American Chemical Society Earle Barnes Award for Leadership in Chemical Research Management.

Dr. LaMattina is a Senior Partner and a member of the Board of Directors of PureTech Health.  He serves on the Board of Directors of Ligand Pharmaceuticals, Immunome and Vedanta.   Dr. LaMattina also serves as a Trustee Associate on the Board of Trustees of Boston College.

133. Pharma & Profits, John LaMattina, former Pres. of R&D, Pfizer, Senior Partner, PureTech Health

Synopsis: 
Joel Schneider, Ph.D. and Robert Kotin, Ph.D. are the President & CEO and Founder & Chief Technology Advisor, respectively, of Carbon Biosciences, an emerging leader in the development of novel parvovirus-derived gene therapies. Joel and Robert sit down with host Rahul Chaturvedi to discuss the arc of their careers, how the AAV field has changed over the last decade, and how they approach building out their team at Carbon. They also talk about Carbon’s focus on cystic fibrosis and the implications of The Cystic Fibrosis Foundation investing in their Series A. Finally, they both weigh in on what excites them when thinking about the future of gene therapy. 

Biographies: 
Dr. Joel Schneider joined Carbon as CEO in 2022, after serving as Chief Operating Officer at Solid Biosciences. As Solid’s first employee, he played an instrumental role in building the company’s unique disease-focused business model. Dr. Schneider is an accomplished biosciences executive with a track record of achievement in identifying, developing, and financing high potential therapeutic modalities and has diverse leadership experiences across R&D, technical and corporate operations, and corporate development organizations.
 
Dr. Schneider holds a Ph.D. from Rutgers University and an undergraduate degree from Brandeis University and is the author of numerous peer-reviewed articles related to Duchenne and stem cell biology. He completed a postdoctoral fellowship at Harvard University in the Department of Stem Cell and Regenerative Biology, where he characterized and developed the small molecules that enhance skeletal muscle regeneration.

Dr. Robert Kotin has been a leader in adeno-associated virus (AAV) research for 35 years, focusing on the molecular biology of the virus’s non-structural proteins and then leveraging this understanding to develop novel AAV vectors for somatic cell gene therapy. Beginning as a postdoctoral fellow at Cornell University Medical Center, Dr. Kotin discovered a common integration site for AAV DNA in human chromosome 19, which he designated AAVS1 locus. He spent most of his career in the Intramural Research Program at the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH), first as a tenure-track investigator and then as a tenured senior investigator and Head of the Laboratory of Molecular Biology and Gene Therapy. 

While at the NIH, Dr. Kotin’s laboratory invented and developed a scalable recombinant adeno-associated virus (rAAV) production process in Sf9 cells which was licensed by UniQure, ThermoFisher, Voyager, Biomarin, and others and was used to produce Glybera™, the first rAAV product granted regulatory agency approval for sale. Additional research from the Kotin lab resulted in the discovery of an AAV replicative product that has been described as closed-ended linear duplex DNA (ceDNA) and became the basis of the non-viral gene therapy company Generation Bio (NASDAQ: GBIO). 
 
Dr. Kotin served as vice president of virology and gene therapy at Voyager Therapeutics from 2014 to 2016. Since 2016, he has served as an adjunct professor at UMass Medical School, where his research interests include vectorizing and characterizing ancestral parvoviruses based on inferred sequences from endogenous virus elements (EVEs) as novel gene therapy vectors.

Dr. Kotin earned his B.A. in biology from the University of California, Santa Cruz, and his doctorate in microbiology from Rutgers University and the University of Medicine and Dentistry of New Jersey (now Robert Wood Johnson Medical School).

Novel viral vectors in gene therapy, Joel Schneider, CEO & Robert Kotin, Founder, Carbon Biosciences

Synopsis: 
Garo Armen, Ph.D., is the Chairman and CEO of Agenus, an immuno-oncology company with the goal of treating cancers with novel combinations utilizing its unique portfolio of checkpoint antibodies, tumor microenvironment modifiers, vaccines and adjuvants. After receiving his Ph.D. in chemistry, Dr. Armen worked on Wall Street where he specialized in specialty pharmaceutical companies as well as biotech. Dr. Armen discusses how his personal history was a driving force behind founding Agenus, as well as his perspective on immunology and immunotherapy. He talks about Agenus’s approach to bringing curative therapies to cancer patients by harnessing the power of the immune system. He also discusses his approach to hiring, leveraging external providers and team building. 

Biography: 
Dr. Garo Armen serves as Chairman and Chief Executive Officer of Agenus Inc., which he co-founded in 1994. Under his leadership, Agenus has been advancing breakthrough scientific technologies and immunotherapeutic products. In addition, Garo oversaw the successful restructuring of the biopharmaceutical company Elan Corporation, plc, where he served as Chairman of the Board of Directors. Garo currently acts as Chairman of the Board of Protagenic Therapeutics, a biotechnology company focusing on human brain hormones for the treatment of neurological and metabolic disorders. He began his research career at Brookhaven National Laboratory subsequent to which he made a transition to Wall Street, as an analyst and investment banker at EF Hutton and then at Dean Witter Reynolds ( now Morgan Stanley) , cultivating key relationships and stock-market expertise. Garo received his PhD in physical chemistry from the City University of New York.

Leadership in revolutionizing cancer immunotherapy, Garo Armen, Ph.D., Chairman & CEO, Agenus

Synopsis: 

In this episode, host Rahul Chaturvedi interviews Sarah Boyce, President & CEO of Avidity Biosciences, as she shares her dynamic journey from big pharma to leading groundbreaking advancements in RNA therapeutics. Sarah delves into overcoming drug delivery challenges, the transformative potential of genetic medicine, and Avidity’s mission to redefine rare disease treatments. She also offers candid insights on leadership, the importance of cultivating a strong company culture, and balancing personal well-being for long-term success. This episode is essential for those eager to explore the future of biotech and the next wave of medical innovation.

Biography:

Sarah Boyce joined Avidity as President and Chief Executive Officer and a member of the Board of Directors in October 2019. She has more than 25 years of global leadership experience in both pharmaceutical and biopharmaceutical companies. Sarah’s tenure at Avidity has been marked by transformative leadership, starting with the company's successful Series C funding round and IPO. She continues to drive the company’s evolution from a research and development entity to a biopharmaceutical company through the advancement of three therapies into clinical development and the expansion of the broad utility of the company’s proprietary RNA technology. Prior to joining Avidity, Sarah held the position of president and a member of the board of directors of Akcea Therapeutics. She previously held executive roles in business development and global operations for leading life sciences companies including Ionis Pharmaceuticals, Forest Laboratories, Alexion Pharmaceuticals, Novartis Oncology and Roche. Sarah was named a Healthcare Technology Report Top 25 Biotech CEO in 2022 and has been named one of Fiercest Women in Life Sciences. Sarah currently serves as a member of the board of directors at OmniAb, Inc., Contineum Therapeutics, Inc., and Abcuro, Inc. Sarah holds a BSc (Hons) degree in microbiology from the University of Manchester, England.

Breaking Biotech Barriers: Avidity President & CEO Sarah Boyce on RNA’s Next Frontier

Synopsis: 

Explore the forefront of biotech innovation as host Rahul Chaturvedi interviews Dr. Dave Bearss, Co-Founder & CEO of Halia Therapeutics, in this engaging episode of Biotech 2050. Dr. Bearss shares the story behind Halia’s pioneering genetic discoveries and their mission to tackle Alzheimer’s disease. Learn about the science driving breakthrough therapies that target neuroinflammation, offering hope in the fight against neurodegenerative disorders. Packed with insights and inspiration, this episode is a must-listen for anyone interested in the future of healthcare and biotech innovation.

Biography:

Dr. David J. Bearss, a serial entrepreneur and pharmaceutical innovator, has over two decades of experience spanning academic and industrial roles. His expertise lies at the intersection of structure-based small-molecule drug discovery and the utilization of genetic model systems for drug discovery. Dr. Bearss's career is marked by significant achievements, with a strong foundation in translational research focused on drug advancement to the clinic and using genetic markers for predictive drug sensitivity.
Notably, Dr. Bearss has discovered 16 compounds that have successfully navigated from discovery in the lab to IND into clinical development. His entrepreneurial experience is evident through his roles as the co-founder of eight biotechnology companies. More importantly, his unwavering commitment to advancing novel drug development truly sets him apart.
Before taking on his role as chief scientific officer at Halia in January 2021 and assuming the CEO position in March 2022, Dr. Bearss served as the CEO of Tolero Pharmaceuticals, an organization later acquired by Sumitomo Dainippon Pharma in 2017. His tenure as chief scientific officer at Montigen Pharmaceuticals, followed by its acquisition by SuperGen Inc., demonstrates his dedication to driving early-stage drug discovery and development. At SuperGen, he continued to develop his expertise in these critical areas.
Dr. Bearss's academic career is equally impressive. It led to his founding role as the Center for Investigational Therapeutics Co-Director at the Huntsman Cancer Institute. He also held academic positions as an Associate Professor in the Department of Oncological Sciences at the University of Utah and as an Associate Professor of Physiology and Developmental Biology at Brigham Young University, demonstrating his deep knowledge and expertise in these fields.
Dr. Bearss's academic career began with a Ph.D. in cell biology from the University of Texas Health Science Center in San Antonio, Texas, and a post-doctoral fellowship at the Institute for Drug Development at the Cancer Therapy and Research Center also in Texas. He has won several awards for his entrepreneurial and scientific achievements, including the Utah Governor's Medal of Science and BIO Utah Entrepreneur of the Year.

Dr. Dave Bearss, Co-Founder & CEO of Halia, on Pioneering Genetic Discoveries to Defeat Alzheimer’s

Synopsis: 

Abe Ceesay, CEO of Rapport Therapeutics, sits down with host Rahul Chaturvedi to reveal how precision neuroscience is driving revolutionary treatments for neurological disorders. They explore Rapport’s cutting-edge lead program targeting focal epilepsy and discuss the groundbreaking advancements that are reshaping the landscape of drug development. Abe also shares his dynamic leadership journey, offering insights into the biotech industry’s future and how innovative approaches are delivering life-changing treatments. Don’t miss this powerful discussion on the future of precision medicine and the hope it brings to patients with neurological conditions.

Biography:

Abe brings nearly two decades of biopharmaceutical industry experience to Rapport. He served as President of Cerevel Therapeutics from May 2021 through February 2023, and was previously CEO of Tiburio Therapeutics, where he built a fully integrated company that led to the investigational new drug enablement for a rare neuroendocrine tumor. Prior to joining Tiburio, Mr. Ceesay held positions including Chief Operating Officer at scPharmaceuticals, Head of Commercial at Keryx Biopharmaceuticals, Vice President of Marketing at Ironwood Pharmaceuticals, and roles of increasing responsibility at Sanofi, formerly Genzyme. Mr. Ceesay serves as Chairman of the Board for Life Science Cares and on the Board of Trustees at The Museum of Science in Boston. He earned his bachelor’s degree from Ithaca College and Master of Business Administration from Suffolk University’s Sawyer School of Management.

Precision Neuroscience Breakthroughs: Abe Ceesay, CEO of Rapport Therapeutics I Future of Biotech

Synopsis: 

Discover how Bitterroot Bio is poised to revolutionize cardiovascular health in this captivating conversation between host Rahul Chaturvedi and CEO Pavan Cheruvu. Pavan opens up about his inspiring journey from engineering to leading a biotech company at the forefront of cardio-immunology. Learn how his visionary leadership is driving innovative solutions to combat atherosclerosis—one of the world’s deadliest diseases. Delve into Bitterroot Bio's cutting-edge approach, blending scientific breakthroughs with bold strategies to create life-saving treatments while overcoming the hurdles of drug development in an ever-changing biotech landscape.

Biography:

Dr. Pavan K. Cheruvu is the President and Chief Executive Officer at Bitterroot Bio. Prior to joining Bitterroot, Dr. Cheruvu was an early member of the executive team at Roivant Sciences and served as President and CEO of Sio Gene Therapies. Over the course of his career, he has worked with multiple biotechnology and medical device companies, as well as in the public sector, with focus areas spanning neurology, oncology, women’s health, and cardiology. Dr. Cheruvu previously worked as a management consultant at McKinsey & Company, where he focused on R&D strategy and transformation for biopharmaceutical firms across North America, Asia, and Europe.

Dr. Cheruvu holds a BS in biomedical engineering, electrical engineering, and chemistry from Duke University and an MSc in computer science from the University of Oxford, where he was a Rhodes Scholar. He went on to earn an MD from Harvard Medical School and MIT. Dr. Cheruvu completed his residency in internal medicine at Johns Hopkins Hospital and continued his training as a clinical fellow in cardiovascular medicine at the University of California, San Francisco. He currently resides in the San Francisco Bay Area with his wife and daughter.  He serves on the Executive Leadership Team of the American Heart Association’s Research Roundtable, and the Board of Advisors of Life Sciences Cares Bay Area.

Revolutionizing Heart Health: Bitterroot Bio’s Bold Vision with CEO Pavan Cheruvu

Biotech2050 Host, Rahul Chaturvedi, engages with Gene Mack, Interim CEO and CFO of Gain Therapeutics, as he shares his journey from aspiring neurosurgeon to biotech leader. Gene reflects on his career shift from clinical research to Wall Street and eventually operational roles in biotech. He details the development of Gain's lead asset, GT02287, which targets Parkinson's disease by aiming for disease modification rather than symptom management. Gene also discusses the challenges of biotech leadership, running clinical trials, and navigating the financial landscape, highlighting the dynamic intersection of science, business, and innovation in neurodegenerative diseases.

Gene Mack, Interim CEO & CFO of Gain Therapeutics: Leading the Charge in Parkinson's Breakthroughs

Synopsis: 

Host Rahul Chaturvedi leads an insightful conversation with Dr. Kristin Yarema, President and CEO of Poseida Therapeutics. Kristin shares the inspiring journey of her career, from her roots in science to leadership roles in big pharma, culminating in her move to biotech entrepreneurship. She reflects on pivotal experiences at Novartis and Amgen, her deep-seated passion for oncology and autoimmune diseases, and the exciting leap into the field of cell therapy.

Kristin unveils Poseida’s innovative genetic engineering toolkit and the company’s advancements in allogeneic cell therapies, spotlighting their potential to revolutionize treatment for conditions like multiple myeloma. She delves into the challenges and opportunities within the cell therapy space, underscoring Poseida's strategic partnerships and commitment to transformative solutions. With candid reflections on the lessons learned as a first-time CEO, Kristin offers valuable insights on fostering cohesive company culture and shares career advice for aspiring biotech professionals.

An essential listen for anyone drawn to biotech innovation, the future of cell therapy, and leadership strategies at the intersection of cutting-edge technology and patient care.

Biography:

Dr. Yarema was appointed President and Chief Executive Officer of Poseida and named to the Board of Directors in January 2024. She joined Poseida as President, Cell Therapy in April 2023, bringing extensive biopharmaceutical experience in oncology and allogeneic T cell immunotherapy. Prior to Poseida she served as Chief Commercial Officer at Atara Biotherapeutics, where she led the commercialization of EBVALLO™️, which became the world’s first marketed allogeneic T cell therapy after receiving regulatory approval in Europe for the treatment of a rare lymphoma. Previously Dr. Yarema held a series of U.S. and global commercial leadership roles at Amgen, including most recently Vice President & Therapeutic Area Head for Global Product Strategy & Commercial Innovation in Hematology-Oncology. Earlier in her career, Dr. Yarema worked at Novartis and McKinsey & Company. Dr. Yarema holds a Ph.D. in Chemical Engineering from University of California, Berkeley and is a graduate of Stanford University, where she earned a B.S. in Chemical Engineering and a B.A. in English. She is an officer and member of the board of directors of the Alliance for Regenerative Medicine and serves on the board of directors of the Celiac Disease Foundation.

Pioneering Advances in Cell Therapy: Kristin Yarema, President & CEO of Poseida Therapeutics

Synopsis: 

Join host Alok Tayi as he welcomes David Meeker, CEO of Rhythm Pharmaceuticals, for an inspiring conversation on the transformative journey of rare disease biotech. David shares his incredible path from practicing physician to biotech visionary, recounting his experiences at Genzyme, where he helped shape the rare disease business model and set the stage for a wave of life-changing innovations.  

In this episode, David dives deep into the breakthroughs and hurdles of developing therapies for rare diseases, the pivotal role of patient-centric approaches, and how advancements in precision medicine are reshaping treatment for conditions like genetic obesity. He also explores the evolving relationship between biotech and big pharma, the critical impact of regulatory decisions, and the essential elements of building a thriving biotech company today.  

Don’t miss this captivating discussion packed with actionable insights, industry wisdom, and a look at the future of rare disease therapeutics.

Biography:

Dr. David Meeker, a member of Rhythm’s Board of Directors since 2015 and Chairman of the Board since 2017, was appointed President and Chief Executive Officer of the Company in July 2020. Most recently, he served as President and CEO of KSQ Therapeutics for approximately three years. Previously, David was the Executive Vice President and Head of Sanofi Genzyme, the specialty-care global business unit of Sanofi that focused on rare diseases, multiple sclerosis, oncology, and immunology. He joined Genzyme in 1994 as Medical Director and, over the course of his tenure, served the company as Vice President of Medical Affairs, Chief Operating Officer, and Chief Executive Officer. He led Genzyme’s commercial organization and global market access functions and managed the launch of several treatments for rare genetic diseases, including Aldurazyme®, Fabrazyme® and Myozyme®. Prior to his tenure with Genzyme, David was Director of the Pulmonary Critical Care Fellowship at the Cleveland Clinic and an Assistant Professor of Medicine at Ohio State University. Dr. Meeker earned his MD from the University of Vermont Medical School and completed the advanced management program at Harvard Business School.

David Meeker, CEO of Rhythm Pharmaceuticals, on Rare Disease Breakthroughs & Biotech’s Future

Synopsis: 

Host Alok Tayi sits down with Clare Terlouw, Head of Ventures at LifeArc Ventures, to explore biotech investing from an LP perspective. Clare shares her unique journey—from physiotherapy to investment banking and, ultimately, leading venture investments at a medical charity. The conversation delves into LifeArc’s role in bridging the funding gap for biotech innovation, the challenges of attracting LP capital, and the future of biotech investing. If you're curious about how a medical charity strategically deploys capital while fueling scientific breakthroughs, this episode is a must-listen!

Biography:

Clare Terlouw is Head of LifeArc Ventures, responsible for LifeArc’s portfolio of direct and LP investments across the life sciences sector. The venture investment fund focuses on early stage life sciences companies at seed to Series A, with significant follow-on investment reserved for successful portfolio companies. 
Clare has significant expertise in funding innovative life sciences companies in the private and public markets. She was previously Head of Corporate Development at Syncona Investment Management Ltd, a FTSE250 healthcare investment trust which builds and invests in life science companies, and has more than 15 years of biotech and healthcare financing experience as a UK investment banker at Nomura, Numis Securities and Peel Hunt. Clare was a physiotherapist in Canada prior to moving into finance.
Clare is a board member of the UK Biotechnology Industry Association and director of a number of venture-backed companies.

Clare Terlouw, Head of LifeArc Ventures, on Bridging Biotech’s Funding Gap & Investing for Impact

Synopsis: 

In this thought-provoking episode of Biotech 2050, host Alok Tayi sits down with Liam Killingstad, Member at Finiam Investments, to unpack the growing influence of family offices in biotech. Driven by his own family's experience with rare cancers, Liam shares how that journey sparked Finiam's deep dive into biotech investing and the co-creation of companies like Khora Therapeutics.

From the untapped power of family offices to the strategies they use to enter high-stakes sectors like biotech, Liam offers a rare, behind-the-scenes look at how mission-driven capital is shaping the future of healthcare innovation.


Biography:

Liam Killingstad is an experienced finance and operations professional in the biopharma, healthcare, and investment sectors. As Co-Founder and Senior Vice President of Finance & Operations at KHORA Therapeutics, Liam works closely with the C-suite to drive strategic initiatives, including the development of multi-asset portfolio construction and complex financial model building in support of executing oncology-focused asset acquisitions across global markets.

Prior to KHORA, Liam served as Chief of Staff at SHEPHERD Health, a precision oncology diagnostics company where he played a pivotal role in securing bridge financing, managing investor relations, and establishing strategic partnerships, including joint ventures that expanded SHEPHERD's precision diagnostics capabilities. He was also instrumental in advocating for federal legislation to improve access to molecular diagnostics for cancer patients.

Liam's financial expertise was honed during his time as an investment banking associate at Goldman Sachs, where he managed transactions exceeding $2 billion in the renewable energy and infrastructure sectors. He has a proven track record of structuring complex financial models, leading investor roadshows, and crafting innovative financing solutions for high-impact projects.

In addition, Liam serves as Operating Partner at Finiam Investments, a European-based family office. He leads due diligence efforts for investments across biotech, digital health, cleantech, and media, supporting the portfolio with strategic planning, financial modeling, and capital formation.

Liam holds a Bachelor of Science in Finance and Economics, graduating magna cum laude from Case Western Reserve University, where he was a varsity baseball captain and recognized for academic excellence. Born and raised in Germany and various other European cities, Liam brings a global perspective to his work and leadership in life sciences and finance.

Liam Killingstad on How Family Offices Quietly Fuel Biotech’s Boldest Innovations

Synopsis:
 
Host Rahul Chaturvedi welcomes back Rachel Haurwitz, President & CEO of Caribou Biosciences, for a deep dive into the future of CRISPR-based genome editing and its transformative impact on cell therapy. As a pioneer in the field, Rachel shares the evolution of off-the-shelf CAR T therapies and how Caribou Biosciences is tackling some of the biggest challenges in biotech.

With four ongoing Phase 1 trials in lymphoma, multiple myeloma, AML, and lupus, Caribou is leading the charge in making CAR T therapies more scalable, accessible, and cost-effective. Rachel also discusses Caribou’s journey from a private startup to a publicly traded company, the role of strategic partnerships like Pfizer’s equity investment, and how biotech companies can navigate today’s uncertain funding landscape.

She reflects on lessons from co-founding Caribou at just 26, the evolution of biotech entrepreneurship, and why raising more capital than you think you need is crucial. Plus, she shares her perspective on leadership, industry trends, and the importance of diversity in biotech, as seen during JPMorgan’s ‘Pink Tuesday’ movement.
From cutting-edge science to strategic decision-making, this episode is packed with insights for biotech professionals, investors, and anyone fascinated by the future of gene editing and cell therapy.

Biography:

Rachel is a co-founder of Caribou Biosciences and has been its president and chief executive officer and a director since the company’s inception in 2011. Rachel is an inventor on patents and patent applications covering multiple CRISPR-based technologies, and has co-authored several scientific papers in high-impact journals characterizing CRISPR-Cas systems. In 2014, she was named by Forbes Magazine to the “30 Under 30” list in Science and Healthcare, and in 2016, Fortune Magazine named her to the “40 Under 40” list of the most influential young people in business. In 2018, the Association for Women in Science recognized Rachel with the annual Next Generation Award. She serves on the board of directors for Biotechnology Innovation Organization (BIO). Rachel earned an AB in biological sciences from Harvard College and a PhD in molecular and cell biology from the University of California, Berkeley.


Revolutionizing CAR T with CRISPR: Rachel Haurwitz, President & CEO of Caribou Biosciences

Synopsis: 

How do you build a biotech company that disrupts drug discovery and delivers real impact? In this episode of Biotech 2050, host Rahul Chaturvedi speaks with Raj Devraj, President & CEO of Rectify Pharmaceuticals and Venture Partner at Atlas Venture.

Raj shares his journey from big pharma to biotech entrepreneurship, the science behind Rectify’s groundbreaking approach to drugging membrane proteins, and how his team is tackling rare hepatobiliary diseases with small-molecule therapies.

He also dives deep into biotech innovation, smart capital strategy, M&A trends, and the power of hiring the right talent. Whether you’re a biotech founder, investor, or science enthusiast, this episode is packed with insights on building, funding, and scaling a biotech startup in today’s competitive landscape.

Biography:

Rajesh (Raj) Devraj, Ph.D., is President and Chief Executive Officer of Rectify Pharma and a Venture Partner at Atlas Venture. Throughout his career, he has been focused on creating and building groundbreaking biotech companies. Prior to Rectify, Raj co-founded Disarm Therapeutics with Atlas and served as its Chief Scientific Officer prior to its acquisition. Before Disarm, he served as Chief Scientific Officer of Atlas-founded Padlock Therapeutics. Prior to his tenure at Atlas, Raj served in senior executive roles at Euclises & Deciphera Pharmaceuticals and at Jubilant Life Sciences. In addition, Raj spent 14 years in positions of increasing responsibility with Pfizer Global R&D and the legacy Pharmacia and Searle companies. Raj also serves on the boards of directors for several biotech companies. Over a 25-year career in large pharma and biotech, Raj has led discovery, early clinical development, and strategic planning teams that have advanced multiple candidates into clinical trials for refractory cancers, autoimmune diseases, IPF, diabetic nephropathy, COPD, and pain. Raj received his B.S. in Pharmacy from the University of Mumbai, and Ph.D. in Medicinal Chemistry from Duquesne University.


Raj Devraj, President & CEO - Rectify Pharma, on Drug Discovery, Biotech Breakthroughs & Growth

Synopsis: 

In this episode of Biotech2050, host Rahul Chaturvedi sits down with Neil F. McFarlane, President and CEO of Zevra Therapeutics, to explore his unique leadership journey from military nurse to biotech executive. Neil shares reflections from his time at Genzyme and UCB, insights on running a rare disease-focused biotech, and the art of mission-driven leadership. He dives into Zevra’s recent therapeutic milestones, regulatory strategies, and the importance of reflection in high-stakes environments. This conversation offers powerful takeaways for anyone navigating biotech leadership, board management, or rare disease innovation.

Biography:

Neil F. McFarlane took the reins as President and CEO of Zevra Therapeutics, a commercial-stage rare disease therapeutics company, in October 2023, bringing with him a wealth of experience in the biopharma industry and specific expertise in neurological and rare diseases. Before joining Zevra, he served on the board of Collegium Pharmaceutical Inc. from 2022 to 2024 and was the CEO of Adamas Pharmaceuticals, Inc., a biopharmaceutical company developing treatments for neurological diseases, from 2019 until its acquisition by Supernus Pharmaceuticals in 2021.
Prior to Adamas, Mr. McFarlane was Chief Operating Officer at Retrophin, Inc. (now Travere Therapeutics, Inc.), from 2016 to 2019, where he managed day-to-day operations. He also held roles of increasing responsibility at UCB, Inc., Genzyme Corporation (now Sanofi), and Sangstat Medical Corporation, which was acquired by Genzyme.

Neil F. McFarlane, President & CEO of Zevra Therapeutics, on Leading Rare Disease Innovation

Synopsis: 

Building in biotech isn’t for the faint of heart—especially during a market downturn. 

But that’s exactly when Steve Tregay, Managing Partner at Mission BioCapital, thrives. A seasoned entrepreneur and founder of Forma Therapeutics, Steven has navigated biotech’s toughest cycles—and emerged stronger each time.

Hosted by Rahul Chaturvedi, this conversation dives into what it really takes to launch and scale biotech companies: from mastering the evolution of the CEO role to raising nearly $900M through strategic partnerships, to knowing when it’s time to pass the torch.

Steve also shares how Mission BioCapital is rewriting the playbook for early-stage innovation through its Platinum Program, offering $500K and lab access to science founders ready to launch bold new ideas.

Real talk, real strategies, and a blueprint for building lasting biotech companies—especially when its hardest.

Biography:

Steve Tregay, PhD is a Managing General Partner based in our Cambridge office. He focuses on new therapeutics investments with a particular emphasis on company creation opportunities as well as on overall management of the firm. Within the Mission BioCapital portfolio, he is currently founding CEO and board member of Arclight Therapeutics, LLC, a founding board member at Jupiter BioVentures LLC, and has board roles at Vedere Bio and Nocion Therapeutics. In addition, Steve serves as Chairman of the Board of Directors at LabCentral. He is a Harvard Blavatnik Biomedical Accelerator Advisory Committee member and is a member of the board of advisors for the non-profit Life Sciences Cares.

Previously, Steve was the Founder and CEO of FORMA Therapeutics. Additional roles held prior to his engagement at FORMA include Managing Director for the Novartis Venture Fund and Executive Director & Head of Strategic Alliances for Oncology, Ophthalmology and Technologies at the Novartis Institutes for BioMedical Research. Prior to Novartis, he held roles in research and business development at Array BioPharma.

Steve received his doctoral and Master’s degrees in organic chemistry from Harvard University and a Bachelor’s from Davidson College.

Steve Tregay on Leading Mission BioCapital as Managing Partner & Fueling Early-Stage Biotech

Synopsis: 

What happens when a former journalist becomes one of biotech’s boldest investors? Meet Stephanie Sirota, Chief Business Officer and Partner at RTW Investments, who helped grow the firm from $27 million in assets to a global biotech force. In this engaging conversation with host Rahul Chaturvedi, Stephanie shares her unconventional path into the industry, and how a mission-driven, science-led investment strategy has guided RTW’s approach across public markets, private deals, and company creation.

Stephanie reflects on the evolution of biotech financing, why GLP-1 drugs are just getting started, and how RTW is preparing for changes in U.S. healthcare policy. She also unpacks how the firm sources opportunities, evaluates risk, and sticks to long-term conviction even in volatile markets. For Stephanie, great biotech investing starts with deep research, strong science, and a relentless focus on patient outcomes.

Whether you're an investor, operator, or simply curious about the future of medicine, this conversation is packed with insights on building bold bets—and the staying power behind them.

Biography:

Stephanie leads a team at RTW overseeing business development, strategic partnerships, communications, and investor relations.

Her background in investment banking and expertise in financial markets has helped position the firm as both a partner to life sciences companies and a steward of investors’ capital. Stephanie also manages RTW’s relationships with key partners including banks, academic institutions, corporations, investors, and NGOs. She has led the firm’s entry into the UK and European markets and serves as a director of the RTW Biotech Opportunities Ltd, a publicly traded investment fund listed on the London Stock Exchange.

Prior to joining RTW, she served as director at Valhalla Capital Advisors, a macro and commodity investment manager. Stephanie also worked in the New York and London offices of Lehman Brothers, where she advised on various Merger & Acquisitions, IPOs, and capital market financing transactions with a focus on cross-border transactions for the firm’s global corporate clients.

Stephanie graduated with honors from Columbia University and also received a Master’s Degree from the Columbia Graduate School of Journalism.
She serves as president of the RTW Foundation; and co-chair of Council of the New York Philharmonic.

Stephanie Sirota, CBO & Partner at RTW Investments, on Biotech Investing, Policy & Bold Bet Building

Synopsis: 

What does bold biotech leadership look like in 2025?

In this episode of Biotech 2050, host Alok Tayi sits down with Stacy Lindborg, President & CEO of Imunon, to discuss bold innovation in ovarian cancer treatment and how harnessing the immune system through targeted gene therapy is reshaping survival outcomes.

Stacy shares insights from her 30-year career—from her statistical roots at Eli Lilly to her mission-driven leadership at Imunon. She highlights the groundbreaking results from Imunon’s IL-12 plasmid platform, which is showing a remarkable 13-month overall survival advantage in ovarian cancer patients and is now entering Phase 3 trials.

They also discuss the evolving biotech landscape, how adaptive trial designs and AI are unlocking clinical potential, and why cultivating a bold, transparent company culture is key to advancing transformational science.

Biography:

Stacy R. Lindborg, PhD, was appointed President and Chief Executive Officer of Imunon in May 2024.  Dr. Lindborg has served on Imunon’s Board of Directors since June 2021. Dr. Lindborg has nearly 30 years of pharmaceutical and biotech industry experience with a particular focus on R&D, regulatory affairs, executive management and strategy development. She has designed, hired and led global teams, guiding long-term vision for growth through analytics and stimulating innovative development platforms to increase productivity. Prior to joining Imunon, Dr. Lindborg was Executive Vice President and Co-Chief Executive Officer at BrainStorm Cell Therapeutics where she will remain a member of the company’s Board of Directors. At BrainStorm she was accountable for creating and executing clinical development strategies through registration and launch and progressed its novel cell therapy for ALS through a positive Phase 3 Special Protocol Assessment (SPA) study with the U.S. Food and Drug Administration. She interacted frequently with investors and analysts, represented the company in the scientific community as well as with the media, and played an active role in discussions with potential business partners.

Dr. Lindborg previously was Vice President & Global Analytics and Data Sciences Head, responsible for R&D and marketed products at Biogen. She began her biopharmaceutical career at Eli Lilly and Company where over the course of 16 years she assumed positions of increasing responsibility, including Head of R&D strategy.

Dr. Lindborg received an M.A. and Ph.D. in statistics, and a B.A. in psychology and math from Baylor University. She has authored more than 200 presentations and 90 manuscripts that have been published in peer-reviewed journals, including 20 first-authored. She has held numerous positions within the International Biometric Society and American Statistical Association and was elected Fellow in 2008.


Stacy Lindborg, Imunon President & CEO, on Bold Biotech, IL-12 Immunotherapy & Phase 3 Trials

Synopsis:
What happens when a world-class scientist and a philanthropic legacy collide with one of medicine’s greatest challenges? Dr. Howard Fillit and Mark Roithmayr of the Alzheimer’s Drug Discovery Foundation (ADDF) join host Alok Tayi for an inspiring conversation on bold science, visionary funding models, and the future of Alzheimer’s research. From treating Estée Lauder in the 1990s to building a $100M venture philanthropy engine, they trace ADDF’s evolution into a global leader in high-risk, high-reward drug development. The discussion covers the rise of biomarkers and digital diagnostics, the foundation’s partnerships with visionaries like Bill Gates and Jeff Bezos, and how ADDF’s venture philanthropy approach bridges the “valley of death” in biotech. They also dive into global regulatory challenges, the economic urgency of Alzheimer’s, and why the future lies in prevention, precision medicine, and a patient-first mindset. This episode is a masterclass in scientific grit, ecosystem thinking, and turning urgency into progress.

Biography:
Howard Fillit, MD
Founding Executive Director and Chief Science Officer of the Alzheimer’s Drug Discovery Foundation

Howard Fillit, MD, is a geriatrician, neuroscientist, and innovative philanthropy executive, who has led the Alzheimer’s Drug Discovery Foundation (ADDF) since its founding. Dr. Fillit has held faculty positions at The Rockefeller University, the SUNY-Stony Brook School of Medicine and the Cornell University School of Medicine. In 1987, he joined the Mount Sinai School of Medicine, where he is a clinical professor of geriatric medicine and palliative care, medicine and neuroscience. Dr. Fillit also maintains a limited private practice in consultative geriatric medicine with a focus on Alzheimer's disease and related dementias.

He has authored or co-authored more than 300 publications and is the senior editor of Brocklehurst's Textbook of Geriatric Medicine and Gerontology. Dr. Fillit is the recipient of many awards and honors including the Rita Hayworth Award from the Alzheimer's Association.

Mark Roithmayr
Chief Executive Officer

Mark Roithmayr is an admired nonprofit leader with four decades of experience in both start-ups and mature organizations. As CEO of the ADDF, he is responsible for steering the Foundation’s overall strategy, focus, and business operations. Since joining the ADDF in 2017, the organization has transformed dramatically in impact, scale, presence, and brand. Under his leadership, the ADDF’s revenue has increased five-fold from $17M to over $90M, and mission-related investing has grown over 100%.

He works closely with Dr. Fillit, executive leadership, and the board to advance the ADDF’s mission of accelerating the discovery of drugs to prevent, treat, and cure Alzheimer’s disease and related dementias. His key accomplishments include securing donations from Bill Gates, Jeff Bezos, and MacKenzie Scott, and a 10-figure gift from the Lauder family to cover ADDF’s overhead for the next 20 years.

Dr. Howard Fillit & Mark Roithmayr of ADDF on Alzheimer’s Innovation, Funding & Biomarkers

Synopsis: 
Longevity isn’t just about living longer—it’s about living better. In this insightful episode of Biotech 2050, host Alok Tayi sits down with Sergey Jakimov, Founding Partner at LongeVC, to unpack what it really takes to invest in the future of healthspan.

Blending his experience as a medtech entrepreneur, rare disease patient, and venture capitalist, Sergey shares why LongeVC focuses on practical, science-backed longevity solutions rather than hype-driven moonshots. He explains why aging isn’t a disease, how diagnostics differ from therapeutics in venture ROI, and what makes AI drug discovery a pivotal unlock in modern biotech.

The conversation also explores the rise of pet longevity, the role of lifestyle in aging, and how LongeVC grew from a €20M experiment to a high-performing fund now raising $250M for Fund Two—all with zero write-offs.

For founders, funders, and anyone curious about the intersection of biotech, aging, and real-world outcomes, this episode offers an honest, no-fluff look at building the future of longevity—one evidence-based investment at a time.

Biography:

Sergey Jakimov is a founding partner of LongeVC, a venture capital fund supporting early-stage biotech and longevity-focused founders that are changing the world. He is a serial entrepreneur, having co-founded 3 deep-tech ventures and raised more than $40 million in venture funding for his own ventures and as an entrepreneur in residence. He has worked with several other early-stage companies in the therapeutics space on fundraising, IP protection, and clinical trial strategies, focusing on early treatments in cardiovascular, oncology, and neurodegenerative spaces. He is also a visiting lecturer to several universities on venture capital and intellectual property rights, and he co-authored a master's program in Technology Law for the Riga Graduate School of Law.

Since 2018, he has co-founded medical tech startup Longenesis, a cutting-edge company that unlocks the hidden value of biomedical data and accelerates novel drug treatment & discovery. In 2020 he co-founded LongeVC, and in 2021, he co-founded the Longevity Science Foundation - a non-profit organization advancing the field of human longevity by funding research and development of medical technologies to extend the healthy human lifespan.

He holds a BSc in International Affairs from Rīga Stradiņš University and two MScs in Political Science and Government and Law and Finance from Central European University and Riga Graduate School of Law, respectively. He was named Forbes Latvia 30 Under 30 in technology and healthcare in 2020.


Sergey Jakimov, Founding Partner at LongeVC, on Pragmatic Longevity Investing & Biotech Innovation

Synopsis: 

When an introverted engineer becomes the President & CEO of REGENXBIO, transformation follows. Curran Simpson joins host Rahul Chaturvedi to unpack his unlikely journey from biotech operations to the C-suite—and how that hands-on experience is reshaping gene therapy's future.

They dive into the evolution of REGENXBIO’s pipeline, tackling ultra-rare diseases like MPS II, ambitious plans for Duchenne Muscular Dystrophy, and commercial partnerships with giants like AbbVie. Curran offers hard-earned leadership lessons, honest reflections on scaling science, and insights into how one-time gene therapies could revolutionize treatment in both rare and common diseases.

From clinical nuance to strategic boldness, this is a masterclass in biotech leadership, platform focus, and staying patient-first—no matter how complex the science or market.

Biography:

Curran M. Simpson is the President and Chief Executive Officer and member of the Board of Directors at REGENXBIO. Mr. Simpson previously served as the Company’s Chief Operating Officer. In that role, he led key business functions including Research & Clinical Development, Corporate Strategy, Manufacturing & Quality, Regulatory, and Commercial Operations. Mr. Simpson joined REGENXBIO in 2015 with extensive leadership experience across biopharmaceutical operations and served as the Company’s Chief Technology and Operations Officer before becoming COO. Prior to joining REGENXBIO, he was the Regional Supply Chain Head for North America and Interim Chief Operating Officer at GlaxoSmithKline (GSK). Mr. Simpson earlier served as interim CEO of Human Genome Sciences (HGS), where he led the integration of HGS into GSK, and as Senior Vice President of Operations and Vice President of Manufacturing Operations at HGS. Prior to HGS, Mr. Simpson was Director of Manufacturing Sciences at Biogen. Earlier in his career, Mr. Simpson served in an overseas assignment at Novo-Nordisk Biochem in Denmark and in various senior development and engineer roles at Genentech, working on Herceptin and Avastin, among other roles. Mr. Simpson has an M.S. in surface and colloid science from Clarkson University and a B.S. in chemistry from the Clarkson College of Technology.


Curran Simpson, President & CEO of REGENXBIO, on Gene Therapy, Strategy & Patient-Centered Impact

Synopsis: 
What do courtroom litigation, computational biology, and fibrosis drug development have in common? In this episode of Biotech 2050, host Alok Tayi speaks with Ahmed Mousa, CEO of Vicore Pharma, to explore his unconventional journey from biotech law to the C-suite. Ahmed shares how Vicore is advancing a first-in-class therapy targeting the angiotensin II type 2 receptor to treat idiopathic pulmonary fibrosis (IPF)—a devastating disease with limited options and poor survival. The conversation dives into how AI is reshaping drug discovery, the promise of precision in early-stage candidate design, and the regulatory and data challenges biotech must overcome. Ahmed also reflects on leading a Swedish-listed biotech as an American CEO, and how a patient-first mission continues to fuel bold innovation across continents.

Biography:
Ahmed Mousa is the Chief Executive Officer of Vicore Pharma (VICO.ST), where he leads the company’s mission to advance angiotensin II type 2 receptor agonists for the treatment of idiopathic pulmonary fibrosis and other serious diseases. Under his leadership, Vicore continues to expand its clinical pipeline and global presence in respiratory and fibrotic diseases.
Previously, Ahmed served as Senior Vice President, Chief Business Officer, and General Counsel at Pieris Pharmaceuticals (PIRS). In this role, he was the site head for the company’s Boston office and oversaw business development, portfolio strategy, centralized project leadership, and quality assurance. He also led Pieris’ legal and intellectual property functions, including licensing, corporate governance, and management of the company’s global patent portfolio.
Before joining Pieris, Ahmed was an attorney at Covington & Burling LLP, where he advised pharmaceutical and biotechnology companies on a range of regulatory and intellectual property matters. He also served as a law clerk for the U.S. Court of Appeals for the Third Circuit and began his legal career as an IP associate at Kirkland & Ellis LLP.
Ahmed holds dual undergraduate degrees in Molecular Biology and Government from Cornell University, a Master’s in Biotechnology from Johns Hopkins University, and a J.D. with honors from Georgetown Law, where he was Editor-in-Chief of the Georgetown Journal of International Law. 


Ahmed Mousa, Vicore CEO, on IPF Breakthroughs, AI-Powered Drug Discovery & Global Biotech Leadership

Synopsis: 
Host Rahul Chaturvedi sits down with Jeremy Bender, CEO of Day One Biopharmaceuticals, to explore the bold mission of transforming pediatric oncology. From earning FDA approval for a groundbreaking brain cancer drug to building a culture rooted in execution and empathy, Jeremy shares lessons from big pharma and startups alike. He discusses how to lead through uncertainty, scale with discipline, and stay focused on delivering targeted therapies for underserved patients. They also dive into real-world data, AI’s emerging role in clinical trial design, and why pediatric-first innovation could reshape the future of oncology.

Biography:
Jeremy Bender, Ph.D., M.B.A. has served as our Chief Executive Officer, President and a member of our board of directors since September 2020. Prior to joining Day One, Dr. Bender was Vice President of Corporate Development at Gilead Sciences, a pharmaceutical company, from March 2018 to September 2020.
Prior to that, he was Chief Operating Officer of Tizona Therapeutics from July 2015 to March 2018 and Chief Business Officer of Sutro Biopharma, a biotechnology company specializing in cancer and autoimmune therapeutics, from October 2012 to July 2015. Prior to joining Sutro Biopharma, he was Vice President of Corporate Development at Allos Therapeutics, a biotechnology company focused on cancer treatments, from January 2006 to September 2012.
Dr. Bender also sits on the board of Mereo BioPharma as an independent board member. He started his career in the life sciences practice at Boston Consulting Group, a management consulting company.
Dr. Bender holds a B.S. in Biological Sciences from Stanford University, a Ph.D. in Microbiology and Immunology from the University of Colorado, and an M.B.A. from the MIT Sloan School of Management.


Jeremy Bender, Day One CEO, on Transforming Pediatric Cancer Care & Leading Biotech with Purpose

Synopsis: 
Amy Burroughs, CEO of Terns Pharmaceuticals, joins Alok Tayi to share how she’s leading bold innovation in CML and obesity treatment, driving two high-stakes data readouts in 2025. From a non-linear path through tech, brand management, and Genentech to building resilient biotech teams, Amy reveals why product positioning, tolerability, and mentorship matter just as much as the science. She also shares her take on CEO loneliness, the value of a “personal board of directors,” and what it takes to lead with clarity, grit, and purpose in today’s biotech landscape.

Biography:
Amy Burroughs joined as our Chief Executive Officer and a member of our Board of Directors in February 2024, bringing more than 25 years of leadership experience. Most recently, she served as CEO at Cleave Therapeutics, where she led the company through financings, spearheaded licensing and collaboration deals, and oversaw the clinical development of its investigational therapy, CB-5339, for the treatment of acute myeloid leukemia. Previously, she served as executive in residence at 5AM Ventures and, in parallel, as senior advisor to one of its portfolio companies, Crinetics Pharmaceuticals, during its initial public offering. Earlier in her career, Ms. Burroughs held roles of increasing responsibility in commercial and strategy at Genentech, commercial and business development at other high growth therapeutics companies, talent and governance at Egon Zehnder International, and brand management at Procter & Gamble. Ms. Burroughs earned her M.B.A. from Harvard Business School, where she graduated as a Baker Scholar, and her B.A. in computer science with a minor in economics from Dartmouth College. She is currently a member of the board and audit committees at Tenaya Therapeutics.


Terns CEO Amy Burroughs on CML Innovation, Obesity Drug Breakthroughs & Leading Biotech Forward

Synopsis: 

Some of the most game-changing ideas in healthcare come from unexpected intersections—where engineering meets biology, and where data meets patient urgency. This episode of Biotech 2050 dives into that exact convergence with a look at how one visionary leader helped pioneer blood-based cancer diagnostics.

Co-CEO & Co-Founder of Guardant Health, AmirAli Talasaz, shares the story behind building one of biotech’s most impactful companies. From a graduate student navigating genomics for the first time to raising over $3 billion and leading a public company, he reflects on lessons learned, obstacles faced, and what it takes to create a patient-first culture at scale.

The conversation explores the technology behind liquid biopsies and companion diagnostics, the challenges of insurance reimbursement, and how Guardant’s innovations are helping detect recurrence and screen for early-stage cancers—all through a simple blood test.

Hosted by Biotech 2050 Co-Founder Rahul Chaturvedi, this episode is packed with insights on biotech leadership, pharma partnerships, and building a company that scales with both urgency and heart.

Biography:

AmirAli Talasaz is the co-CEO of the leading precision oncology company, Guardant Health, which he co-founded in 2012 with Helmy Eltoukhy. Prior to co-founding Guardant Health, he was senior director of Diagnostics Research at Illumina and led the efforts for emerging clinical applications of next-generation genomic analysis. Before Illumina, he founded Auriphex Biosciences, which focused on purification and genetic analysis of circulating tumor cells for cancer management. Talasaz received his PhD in electrical engineering and MSc in management science from Stanford University.


Rewriting Cancer: AmirAli Talasaz, Co-CEO of Guardant Health, on Liquid Biopsy, Data & Biotech Grit

Synopsis: 

From stargazing in rural Tennessee to reimagining the future of immune health, Kevin Caldwell’s journey is anything but conventional. In this episode of Biotech2050, Rahul Chaturvedi speaks with the CEO, Co-Founder & President of Ossium Health about how personal experiences with a reactive healthcare system—and a deep curiosity about the universe—sparked a mission to extend human healthspan through regenerative medicine.

Kevin shares how Ossium built the first scalable bone marrow bank sourced from deceased organ donors—unlocking a powerful, overlooked source for life-saving cell therapies. He discusses Ossium’s fully integrated model, commercialization strategy, and why rigorous company-building must go hand-in-hand with scientific ambition.

The conversation unpacks hard-won lessons from raising $130M+, navigating regulatory pathways, and leading with long-term conviction. A bold vision for transforming cell therapy—and a candid look at the mindset needed to build for impact.

Biography:

As CEO, Co-Founder & President of Ossium Health, Kevin Caldwell has built Ossium from a small startup into a clinical stage bioengineering company. Mr. Caldwell set the company’s mission to improve human health through bioengineering and designed its platform-based model for cellular therapeutics development. Mr. Caldwell has led the company’s successful pursuit, negotiation, and execution of more than 50 business relationships, including 5 successful fundraisings and dozens of supply partnerships, clinical partnerships, and commercial contracts with biopharmaceutical companies. After seven years of strategic engagement and networking, Mr. Caldwell drove the team to successfully secure a transformative federal contract with BARDA (Biomedical Advanced Research and Development Authority) that validates Ossium’s innovative approach. This milestone represents the culmination of persistent relationship-building, targeted proposals, and our unwavering commitment to addressing national biomedical challenges through cutting-edge technology and collaborative partnerships.

Prior to founding Ossium, Mr. Caldwell served as an Engagement Manager at McKinsey’s San Francisco office where he advised clients in the biotechnology and healthcare sectors. His projects ranged from due diligence of acquisition targets in the biotech startup ecosystem to restructuring distressed biopharma companies. Mr. Caldwell led more than 20 engagements with more than a dozen clients, leading teams that advised clients on revenue growth, go to market strategy, and organizational restructuring.

Before McKinsey, Mr. Caldwell served as a Senior Investment Associate at Bridgewater Associates where he did quantitative research for the firm’s global macro investments. Mr. Caldwell studied Physics and Economics at MIT before receiving his JD from Harvard Law School. In addition, he is a member of the Young Presidents Organization (YPO), and a Fellow of the Leaders in Tech Program.


Kevin Caldwell, Ossium Health CEO, on Cell Therapy, Vertical Integration & Immune Healthspan

Synopsis: 

When biotech meets bold partnerships, new models of innovation emerge. In this episode of the Biotech 2050 Podcast, host Rahul Chaturvedi welcomes Paul Biondi, Managing Partner at Flagship Pioneering, and Uli Stilz, Vice President, R&D External Innovation Partners at Novo Nordisk, to explore the power of co-creation.

Together, they unpack how Flagship’s pioneering medicines model and Novo’s Bio Innovation Hub intersect to accelerate breakthroughs in obesity, diabetes, and cardiometabolic diseases. They share lessons on building trust, navigating crises, and structuring alliances that go beyond transactions into enduring innovation ecosystems.

From human disease atlases to new frameworks for agile collaboration, this episode offers a rare behind-the-scenes look at how pharma and biotech can partner differently—turning complexity into transformative therapies.

Biography:

Paul Biondi is a Managing Partner at Flagship Pioneering, leading Flagship’s product and partnering capabilities, including Pioneering Medicines, Partnering, and Pipeline and Product Innovation.
In this role, Paul oversees Pioneering Medicines, Flagship's in-house drug discovery and development unit, as well as therapeutic partnering and business development efforts for the Flagship ecosystem, including driving broad institution-wide Innovation Supply Chain partnerships with biopharma companies to jointly conceive and create innovative products.
Paul also works with Flagship company CEOs and their teams to achieve the best attainable value for each company, guiding them in their pipeline strategy, product concepts, R&D execution, and partnering approach. He serves on the boards of Flagship-founded companies, including Tessera Technologies (NASDAQ: TSRA) and Valo Health.
Paul Biondi is Managing Partner at Flagship Pioneering, joining after 17 years at Bristol-Myers Squibb (BMS), where he served as SVP of Strategy & Business Development and held leadership roles in R&D. He previously spent nine years at Mercer Management Consulting. Paul earned his MBA from the Kellogg School of Management at Northwestern University and his B.A. from Dartmouth College.

Uli Stilz is Corporate Vice President, R&D External Innovation Partners, External & Exploratory Innovation (E2I) at Novo Nordisk., based in Boston. He leads a global R&D team that builds creative partnerships with biotech, venture capital, academia, and research hospitals to co-create next-generation therapeutics in cardiometabolic and rare diseases. Building on the success of the Novo Nordisk Bio Innovation Hub, Uli and the E2I team drive an externally anchored portfolio of collaborations that stimulate global innovation ecosystems and advance Novo Nordisk’s pipeline.

Uli Stilz earned his Master’s in Organic Chemistry from ETH Zürich and a Ph.D. in Biochemistry from the Max-Planck-Institute of Biochemistry in Martinsried, followed by postdoctoral research at Caltech. He began his industry career at Hoechst AG and later Sanofi, where he became Associate VP of the Innovation Unit in the Diabetes Division. Over two decades, he contributed to more than 60 preclinical and clinical drug candidates in cardiometabolic, immunology, and oncology. From 2012–2014, he served as President of the European Federation for Medicinal Chemistry.

In 2014, Uli joined Novo Nordisk in Copenhagen and in 2019 moved to Boston to establish and lead the Bio Innovation Hub, now the External & Exploratory Innovation (E2I) organization. He also serves as Adjunct Professor at the University of Frankfurt, sits on editorial and scientific advisory boards, and holds board roles at the Kendall Square Association and Gensaic, while advising the aMoon Fund.

Co-creating Breakthroughs in R&D: Paul Biondi (Flagship) & Uli Stilz (Novo Nordisk)

In this inaugural episode of Biotech2050, hosts Alok Tayi and Rahul Chatuverdi sits down with Lee Cooper,  a seasoned biotech entrepreneur, lawyer, patient advocate, founder of Enlight Bio and the nonprofit Institute for Genetic Disease Prevention to talk about the importance of patient centricity in today’s modern biotech. 

Cooper writes and speaks on health innovation and bioethics. He has a JD and MBA from Columbia University, and a BA in Religion and Public Policy from Dartmouth College. 

Today, he talked about his journey to the Biotech industry and how he came to founding Enlight Bio.
Apple: 084248

1.  Lee Cooper: Patient advocate and Founder of Enlight Bio

William J. Newell has served as our Chief Executive Officer and a member of our Board of Directors since January 2009. Previously, he served as the President of Aerovance, Inc., a biotechnology company focused on respiratory diseases, from 2006 to 2007. Mr. Newell has also served as the Chief Business Officer and Senior Vice President at QLT Inc., in several senior management positions at Axys Pharmaceuticals, Inc., and has experience as a corporate lawyer. He currently serves on the boards of directors of a private biotechnology company, the Biotechnology Innovation Organization’s Health Section and Emerging Company Section and the California Life Sciences Association, where he also serves as a member of the executive committee. Mr. Newell received an A.B. in Government from Dartmouth College and a J.D. from the University of Michigan Law School. We believe that Mr. Newell is qualified to serve on our Board of Directors because of his experience with various biotechnology companies, including working with and serving in various executive positions in life sciences companies.

47. Next generation cell-free cancer and autoimmune therapeutics, Bill Newell, CEO, Sutro Biopharma

Biotech2050 Podcast is a think tank chronicling the disruptions changing the biotech industry over the next 50 years.

Biotech2050 Podcast

Popular tracks